Supernus Pharmaceuticals Inc. (NASDAQ:SUPN)’s share price fell 1.4% during trading on Thursday . The stock traded as low as $21.51 and last traded at $21.55, with a volume of 235,874 shares changing hands. The stock had previously closed at $21.86.

Several research firms have commented on SUPN. Jefferies Group reissued a “buy” rating and set a $28.00 target price (up previously from $23.00) on shares of Supernus Pharmaceuticals in a research note on Thursday, August 4th. Piper Jaffray Cos. cut shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 target price on the stock. in a research note on Monday, July 18th. Northland Securities cut shares of Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 target price on the stock. in a research note on Monday, July 18th. Finally, Zacks Investment Research cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $24.50.

The firm has a market capitalization of $1.09 billion and a P/E ratio of 45.04. The firm’s 50-day moving average is $22.04 and its 200-day moving average is $17.97.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.13 by $0.05. The business had revenue of $50.40 million for the quarter, compared to analyst estimates of $49.67 million. The firm’s quarterly revenue was up 43.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.03 EPS. Equities research analysts expect that Supernus Pharmaceuticals Inc. will post $0.68 earnings per share for the current year.

In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 3,395 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, July 14th. The shares were sold at an average price of $22.00, for a total transaction of $74,690.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

An institutional investor recently raised its position in Supernus Pharmaceuticals stock. New York State Common Retirement Fund boosted its stake in shares of Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) by 3.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 205,981 shares of the specialty pharmaceutical company’s stock after buying an additional 7,299 shares during the period. New York State Common Retirement Fund owned about 0.42% of Supernus Pharmaceuticals worth $2,768,000 as of its most recent filing with the SEC.

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.